Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Clin Pract Oncol. 2006 Dec;3(12):668-81.

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Author information

  • 1Clinical Research Center, National Institutes of Health, Room 3-5762, Bethesda, MD 20892, USA. muranskp@mail.nih.gov

Abstract

In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.

PMID:
17139318
[PubMed - indexed for MEDLINE]
PMCID:
PMC1773008
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk